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Early quality of life benefits of icodextrin in peritoneal dialysis. related quality of life as perceived by the ESRD patient
Background. The impact of new therapies on patient quality is considerable. Renal replacement therapies such as he-
of life (QOL) is emerging as an important indicator of the modialysis and peritoneal dialysis only partially correctvalue of these therapies. In patients on dialysis, previous QOL
the symptoms experienced by the patients and provokeevaluations have focused mainly on comparative approaches
additional changes in the patient’s lifestyle. Thesesbetween modalities, or on longitudinal trends within a mod-
ality, but few have evaluated technical innovations or introduc- changes can then affect patients’ QOL. Other dialysis
tion of new therapies. The aim of the present study was to as- characteristics such as solutions used in peritoneal dial-
sess the early effects of a new dialysis solution (icodextrin) on
ysis patients also may affect the patient’s QOL. It is impor-the QOL of peritoneal dialysis patients. The QOL is compared
tant to distinguish QOL changes that are associated withwith that of patients on dextrose, and the impact of demographic,
and clinical characteristics on patients’ QOL is examined. the disease itself, dialysis modalities, and other dialysis
Methods. The kidney disease quality of life questionnaire characteristics such as solutions used in peritoneal dial-
(KDQOL) was administered to patients who participated in a ysis. Valid quality of life data can assist patients and pro-phase III double-blind, parallel group, active-controlled trial
viders in making decisions about treatment modalitiesto evaluate the efficacy and safety of a peritoneal dialysis (PD)
solution containing icodextrin in comparison with dextrose PD and is an important component in the advancement of
solution. A total of 93 patients (58 icodextrin, and 35 dextrose) disease treatment in this growing population [1–2].
completed the questionnaire at both baseline and after 13 There is a close connection between quality of life,weeks. In addition to patients QOL, patients’ demographic
morbidity, and mortality in ESRD patients. The hospital-and clinical characteristics were recorded at both baseline and
ization and survival rates tend to be better in patients13 weeks.
Results. Mean change scores from baseline to 13 weeks of with a better QOL. Along with survival and other types
icodextrin patients were substantially higher (5) than dex- of clinical outcomes, patient QOL should be considered
trose, particularly with respect to general health perception,
an important indicator of the effectiveness of the therapyphysical functioning, role-physical, and many KDQOL symp-
they receive. The evaluation of ESRD treatment out-tom items such as lack of strength, washed out or drained, lack
of appetite, faintness or dizziness, dry skin, cramps after an comes and therapy decisions should be based not only
exchange or treatment, cramps during an exchange or treat- on morbidity and mortality rates, but also on a periodic
ment, and muscle spasms or twitching. At 13 weeks, icodextrin
assessment of quality of life outcomes [1].patients had significantly improved symptoms, and rated their
Information on the early QOL of peritoneal dialysishealth in general higher than those patients in the dextrose
group. Upon multivariate analysis, icodextrin contributed sig- patients on different dialysate solutions, however, is lack-
nificantly to the improvement of patients’ mental health, gen- ing. The MIDAS study (a large multicenter study in the
eral health, and symptoms such as muscle spasms or twitching, United Kingdom designed to compare icodextrin-basedcramps during an exchange or treatment, cramps after an ex-
solutions with glucose-based solutions for the overnightchange or treatment, itchy skin, and faintness or dizziness.
Conclusions. Peritoneal dialysis patients treated with ico- dwell) found that, during six months of treatment with
dextrin experienced substantial quality of life improvement at icodextrin, the prevalence of CAPD symptoms (pain dur-
13 weeks after the start of treatment when compared to dex- ing exchange, abdominal fullness, night cramps, loss oftrose patients. Further research is necessary to determine pa-
appetite, constipation, diarrhea, thirst, difficulty main-tients’ quality of life over time in a longitudinal study setting.
taining correct weight, shortness of breath, ankle swell-
ing, tiredness, visual disturbance) was significantly re-
duced compared with glucose despite that total symptomQuality of life (QOL) assessment has become increas-
scores were similar at entry for both treatment groupsingly important in clinical research for end-stage renal
disease (ESRD). The impact of the illness on health- (abstract; Armstrong et al, Nephrol Dial Transplant 11:
A240, 1996). The study demonstrated that after four
weeks of treatment, the change in total symptom scoreKey words: dialysate, renal replacement therapy, CAPD, APD, dex-
trose solution. from baseline in icodextrin group was significantly greater
than that in the glucose group. This difference continued 2002 by the International Society of Nephrology
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and increased over the rest of the trial period (abstract; from “worst possible” to “perfect health.” Each question
is pre-coded numerically, it is then transformed into aArmstrong, ibid).
The goal of the present study is to assess the QOL of scale of 0 to 100; the highest values reflect better QOL
[4]. The reliability and validity of the KDQOL have beenperitoneal dialysis patients 13 weeks after the start of
icodextrin using KDQOL under the conditions of a con- supported by various studies. In an American and Euro-
pean multicenter study, preliminary results showed itstrolled, randomized, double-blind trial. The changes in
QOL while on icodextrin are compared to those of con- value as a predictor for hospitalization and mortality
(abstract; Mapes, ibid) [1].trol subjects using dextrose-based solutions for the long
dwell. The impact of demographic, clinical and dialysis The standard KDQOL instrument was used with only
a minor modification in items of question number 26,characteristics on patients’ quality of life is also exam-
ined. which were adjusted to peritoneal dialysis:
1. “Cramps during dialysis” was changed to, “Cramps
METHODS
during an exchange or treatment.”
Patients and clinical trial design 2. “Cramps after dialysis” was changed to, “Cramps
after exchange or treatment.”A phase III double-blind, parallel group, active-con-
trolled trial was conducted to evaluate the efficacy and 3. “Clotting or other problems with your access site”
was changed to, “Problems with exit site.”safety of a peritoneal dialysis (PD) solution containing
icodextrin in comparison with dextrose PD solution. Two
Data collection and analysishundred eighty-seven patients (175 icodextrin, 112 dex-
trose) were randomized between March 1998 and March The questionnaire booklets were administered to pa-
tients in a consistent manner at each study visit. The1999 [3]. The study period was 52 weeks. The QOL study
was initiated after patient enrollment began therefore completed booklets were reviewed for completeness and
then collected by study monitors during their routinenot all of the patients in the safety trial participated in
the QOL analysis. Quality of life data were collected be- site visits.
Upon conclusion of the trial, the case report formstween October 1998 and March 2000. The KDQOL Ques-
tionnaire (kidney disease quality of life questionnaire) (CRFs) were removed from the QOL booklet and pre-
pared for optical scanning into Microsoft Excel data-was the assessment tool administered to patients. A total
of 58 icodextrin patients and 35 dextrose patients com- sets (Microsoft, Inc., Seattle, WA, USA). Because the
CRFs were designed in Teleform, missing and duplicatepleted the questionnaire at both baseline and week 13.
data could be detected via an on-screen verification pro-
KDQOL questionnaire cess. Subsequent to the scanning and verification pro-
cesses, quality assurance tests were performed to ensureThe KDQOL questionnaire is a validated quality of
life instrument that combines a generic questionnaire, that the original data recorded in the QOL booklet was
successfully transferred to the electronic database.the SF-36, with a disease-specific module. The SF-36 is a
generic instrument that includes 36 items assessing eight Very little missing data were corrected or imputed;
because the QOL data are time sensitive, it is not possibledimensions of functioning and well-being: physical func-
tion (10 items), role limitations caused by physical health to retrieve data once the patient visit has concluded. Per
the KDQOL Scoring Manual, any items that were blankproblems (4 items), bodily pain (2 items), general health
perceptions (6 items), energy/fatigue (4 items), social upon receipt from the sites remained blank. In some
instances, however, values for missing or duplicative datafunction (2 items), role limitations caused by emotional
problems (3 items), and emotional well-being (5 items). were imputed. Missing items from the SF-36 were han-
dled in a manner consistent with the procedures outlinedThe eight dimensions are complemented by a mental
and physical component summary. In each dimension, in the SF-36 Health Survey Manual [5]. If individual
questions were left blank, they were coded as “missing”the respondent receives a score from 0 to 100. The higher
the score, the better the health. The reliability, validity, until the final scoring process was conducted. If a respon-
dent marked two responses that were adjacent to eachand sensitivity of the instrument have been shown in
patients with ESRD (abstract; Mapes et al, J Am Soc other, a response was randomly selected and entered for
that question. The question was left blank and coded asNephrol 10, 249A, 1999) [4]. The disease-specific part of
the instrument includes items directed at the renal dis- “missing” if the respondent marked two non-adjacent
responses.ease (symptoms/problems, effects of kidney disease on
daily life, burden of kidney disease, cognitive function, After transforming the raw QOL data to a 0 to 100
scale, comparisons were made within and between treat-quality of social interaction, sleep). A single overall rat-
ing of health is also included that asks respondents to ment groups. The Student t test was used to assess the
differences between treatment groups at baseline and 13rate their health on a response scale of 0 to 10 ranging
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Table 1. Demographic and clinical characteristics of icodextrinweeks. Paired t tests were used to compare within-group
and dextrose group at baseline
changes in score from baseline to 13 weeks. Responses
Icodextrin Dextroseto the single-item health transition domain were tested
N  58 N  35 P valueausing the nonparametric test. Demographic data were
Demographictested using the t test for continuous variables and non-
Age 54.5 (14.7) 56.06 (12.32) ns
parametric test for categorical variables. All statistical Male 53% 57% ns
Race nstests were performed with the SAS (Release 8.2) package
Caucasian 72% 74%(SAS Institute, Cary, NC, USA). Statistical significances
Hispanic 3% 0%
are reported at the standard P  0.05 level. Asian 9% 3%
Black 14% 23%In addition to testing for statistical significance, the
Other 2% 0%QOL data were analyzed for differences that may be
Clinical
perceived as clinically meaningful. The determination of Primary kidney disease ns
Diabetic nephropathy 28% 31%a clinically meaningful change score (also referred to
Glomerulonephritis 16% 20%as a minimal clinical important difference, MCID) is a
Hypertensive nephropathy 22% 37%
relatively recent pursuit by QOL scientists. The MCID Polycystic kidney disease 7% 3%
Interstitial nephritis 3% 0%can be defined as the smallest difference in score in the
Autoimmune disease 2% 0%domain of interest, which patients perceive as beneficial
Other 22% 9%
and which would mandate, in the absence of troublesome BUN mg/dL 56.0 (17.3) 55.9 (16.5) ns
Creatinine lmol/L 834.1 (258.2) 832.0 (319.9) nsside effects and excessive cost, a change in the patient’s
Hematocrit % 34.2 (5.2) 34.6 (4.1) nsmanagement [6–8].
Hemogloblin % 114.5 (17.5) 115.1 (14.9) ns
QOL scientists use the MCID to determine the sig-
a Two sample t test, nonparametric test as appropriate (significance levelnificance to patients any score differences observed, and 0.05)
b Data are mean (standard deviation)communicate that significance to clinicians who will be
applying the trial results [6–9]. For example, in an at-
tempt to determine the significance to patients of changes
in QOL scores assessed by the European Organization
meaningful [5], clinically meaningful results were definedfor Research and Treatment of Cancer Quality of Life
in this analysis as a 5 point difference between groupsQuestionnaire, Osoba et al have shown that for patients
when comparing the change in mean score from baselinewho indicated “no change” have a mean change in scores
to 13 weeks. Clinical meaningful changes between groupsclose to 0 [8, 9]. For patients who indicated “a little
from baseline to week 13 are reported.change” the mean change in score was about 5 to 10;
for “moderate change,” about 10 to 20; and for “very
much change,” greater than 20. King et al have shown RESULTS
that these MCID changes may reflect real changes in Demographic and clinical characteristics
disease severity [10]. Developers of the condition-spe-
Demographic and clinical characteristics of the twocific Asthma Quality of Life index propose that a 0.5
groups are summarized in Table 1. The two groups werechange (1 to 7 scale) along any of the four subscales
comparable in respect to age, gender, ethnicity, causesrepresents a minimal important difference [11].
of end-stage renal disease (ESRD) and laboratory mea-For most of the measures used in clinical practice little
sures at baseline. Similarly, the two groups were similareffort has gone into defining the MCID. The reason is
for many parameters during the course of the study asthat, through repeated use, clinicians develop an intuitive
summarized in Table 2. No statistically significant differ-sense of the MCID. Clinicians familiar with the tests
ences were found in any of these mean changes fromwould have no difficulty specifying that a 10% drop in
baseline to 13 weeks.diastolic pressure in a hypertensive patient is clinically
meaningful. The same may hold for QOL questionnaires.
KDQOL symptom/problem resultsClinicians who gain experience with a questionnaire de-
Mean scores of the SF-36 component of the KDQOLvelop a sense of the importance of changes seen in pa-
for both icodextrin and dextrose groups at baseline andtients’ scores. However, most QOL questionnaires are
13 weeks and the mean changes between the two timepresently research instruments, and are likely not famil-
points are reported in Table 3. Because the domainsiar to clinicians in terms of their clinical interpretations.
are interrelated, aggregate scores that summarize effectsTherefore, it is important to report MCIDs whenever
across the multiple domains are calculated. The SF-36possible [6–8, 12].
health survey uses factor weights to construct two sum-Consistent with the guidelines set forth by the develop-
mary scores: one more heavily weighted along the physi-ers of the SF-36, which suggest that a 5 to 10 point change
along any of the instrument’s subscales as clinically cal domains [the physical component summary (PCS)
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Table 2. Vital signs and lab values: mean, mean change, and significance of difference in mean change
Mean change in scoreIcodextrin Dextrose
(B to W13)
Baseline Week 13 Baseline Week 13
Vital signs/lab values (N 58) (N  58) (N 58) (N  58) Icodextrin Dextrose P a
Systolic blood pressure (sitting) 139.5 140.3 142.7 136.3 0.8 6.4 ns
Diastolic blood pressure (sitting) 81.5 83.1 80.0 79.3 1.6 0.7 ns
Systolic blood pressure (standing) 134.9 133.6 138.5 127.3 1.3 11.2 ns
Distolic blood pressure (standing) 80.1 80.8 79.7 75.7 0.7 4.0 ns
Weight 75.3 75.7 84.6 85.9 0.4 1.3 ns
BUN 56.0 53.7 56.0 55.2 2.3 0.8 ns
Creatinine 834.1 835.5 832.0 865.3 1.4 33.3 ns
Hematocrit 34.2 33.4 34.6 33.2 0.8 1.4 ns
Hemoglobulin 114.5 111.6 115.1 110.9 2.9 4.2 ns
a Two sample t test comparing the mean change in score between groups
Table 3. KDQOL SF-36 component scores: mean, difference in mean change, and statistical significance
Icodextrin Dextrose
Baseline Week 13 Baseline Week 13 Difference in mean
SF-36 domains (N 58) (N  58) (N 58) (N  58) change score P a
Physical functioning (PF) 57.2 55.2 57.8 50.7 5.2 ns
Role-physical (RP) 52.6 48.7 47.8 38.2 5.6 ns
Bodily pain (BP) 65.2 66.8 66.3 63.9 4.1 ns
General health (GH) 50.5 48.7 46.8 42.1 2.9 ns
Vitality (VT) 55.1 51.1 48.3 46.5 2.2 ns
Social functioning (SF) 78.2 75.9 76.1 71.8 1.9 ns
Role-emotional (RE) 75.3 74.1 61.8 57.8 2.7 ns
Mental health (MH) 76.4 77.2 74.6 70.9 4.5 ns
Physical component summary (PCS) 37.8 37.0 38.3 35.7 1.6 ns
Mental component summary (MCS) 52.5 52.6 49.1 48.5 1.4 ns
a Two sample t-test to detect between-group differences in the mean score change from baseline to Week 13
score], the other more heavily weighted along the mental Changes in detailed symptomatology are described in
Table 5. Statistically significant differences were detectedhealth domains [the mental component summary (MCS)
score]. when the mean change in score was compared between
groups. Cramps during an exchange or treatment, andAt baseline, the two groups were comparable for the
various domains with no significant differences detected overall rating of health favors icodextrin. Problem with
exit site favored dextrose despite that there were nosuggesting a satisfactory success of the randomization
process. While the values of the domains at week 13 statistically significant difference of exit site infections
or peritonitis rate between icodextrin and dextrosewere not statistically different between the two groups,
patients receiving icodextrin had higher mean score group [3].
Two items, faintness or dizziness and muscle spasmschanges reflecting physical function (for example, PF and
RP scores), and mental functioning (such as, MH, SF). or twitching, have P values of 0.08 in mean change score
between groups that favor icodextrin. Since QOL is aBecause domain scores may not be sensitive enough
to uncover improvements in quality of life in specific secondary outcome of the trial, the small sample size
(N  93) may render the trial underpowered to detectareas with the introduction of a new therapy, a detailed
examination of health transition questions and symptom- differences in QOL at the 0.05 level [12]. Because of this
and other limitations, the approach of clinically meaning-atology is required. Table 4 summarizes the patient re-
sponses to the health transition question. For categorical ful differences has been used to explore treatment re-
lated effects. Clinically meaningful differences at base-variables such as heath transitions, nonparametric test
is used. Significance is defined at the standard P  0.05 line, 13 weeks, and mean change comparison between
icodextrin and dextrose group are listed in Table 6.level. While the two groups are similar at baseline, the
group receiving icodextrin showed a better maintenance At baseline, the two groups were comparable for their
quality of life profiles except for a few items: dextroseof QOL perception compared to the group on glucose
based solution. patients scored 5 point or higher than icodextrin patients
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Table 4. KDQOL SF-36 reported health transition (HT)a frequency summary, changes, and statistical significance
Icodextrin Dextrose
N % N % P b
Baseline 56 35 ns
1 Much better now than one year ago 18 32.1% 13 37.1%
2 Somewhat better now than one year ago 11 19.6% 9 25.7%
3 About the same as one year ago 23 41.1% 9 25.7%
4 Somewhat worse now than one year ago 4 7.1% 4 11.4%
5 Much worse now than one year ago 0 0.0% 0 0.0%
Week 13 56 35 ns
1 Much better now than one year ago 17 30.4% 6 17.1%
2 Somewhat better now than one year ago 13 23.2% 8 22.9%
3 About the same as one year ago 17 30.4% 12 34.3%
4 Somewhat worse now than one year ago 7 12.5% 8 22.9%
5 Much worse now than one year ago 2 3.6% 1 2.9%
Changes 0.05
1 Much better now than one year ago 1 7
2 Somewhat better now than one year ago 2 1
3 About the same as one year ago 6 3
4 Somewhat worse now than one year ago 3 4
5 Much worse now than one year ago 2 1
a Question is: Compared to one year ago, how would you rate your health in general now?
b Nonparametric Wilcoxon two-sample test
in the following symptom/problem: joint pain, stiffening clinical variables were those listed in Table 1. Statistical
of joints, easy bruising, dry skin; icodextrin patients significance was defined at the standard 0.05 level.
scored 5 point or higher in blurred vision. The two groups Compared with dextrose, icodextrin was found to be
scored similarly in other dimensions/items. significantly better at improving physical health, mental
At week 13, dextrose group has a 5 point or higher health, muscle spasms or twitching, cramps during an ex-
score than icodextrin group in joint pain and problem change or treatment, cramps after an exchange or treat-
with exit site; icodextrin group has a 5 point or higher ment, itchy skin, and faintness or dizziness. This is very
score in muscle spasms or twitching, cramps during an consistent with findings in section 2 above when compar-
exchange or treatment, itchy skin, lack of appetite, lack ing mean score changes in icodextrin and dextrose
of strength, fatigue, weakness, washed out or drained, groups, which might indicate effective randomization in
and blurred vision. participants of quality of life study.
When comparing baseline to week 13 mean change No domains/items were found to be significantly favor-
scores between groups, icodextrin has a clinically mean- able to dextrose in the regression analysis. The problem
ingful advantage in 13 dimensions/items, while dextrose with exit site was not associated with icodextrin usage.
has an advantage in 1 item. Specifically, icodextrin scores Table 7 reports the regression coefficient estimates
5 points or more higher than dextrose in general health, on icodextrin that were statistically significant and the
physical functioning, role-physical, lack of strength, washed related partial and total explained variances. Partial vari-
out or drained, lack of appetite, faintness or dizziness, ance is the percentage of variance in the QOL domain/
low blood pressure, high blood pressure, dry skin, cramps item score that is explained or accounted for by icodex-
after an exchange or treatment, cramps during an ex- trin only while controlling for other demographic and
change or treatment, and muscle spasms or twitching. clinical characteristics. Total variance is the percentage
Dextrose patients are found to score 5 points or more of the total variation in the QOL domain/score that is
higher than icodextrin only in problems with exit site. explained or accounted for by all the demographic, clini-
Neither treatment demonstrated a 5 points or more ad- cal characteristics, and icodextrin together.
vantage in the other items. All statistically significant estimates related to icodex-
trin are positive indicating favorable impact of icodextrin
Associations between demographic, clinical, and on the specific domain/item. No domains/items were
dialysis solutions and quality of life found to be significantly favorable to dextrose.
Applying the same statistical technique as Merkus et
al, a forward stepwise regression model was used to
DISCUSSIONexplore associations between demographic, clinical, and
Improving or maintaining health-related quality of lifeicodextrin use (with dextrose as reference group) with
quality of life domains/items [13]. The demographic and is an important goal in the clinical management of pa-
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Table 5. KDQOL kidney disease symptom/problem scores: mean, difference in mean change, and statistical significance
Icodextrin Dextrose
Baseline Week 13 Baseline Week 13 Difference in mean
KDQOL symptom/problem scale (N 58) (N  58) (N 35) (N  35) change score P a
Overall, mean 80.3 81.2 81.2 79.4 2.7 ns
SD 11.9 11.3 12.7 14.5
Minimum 43.6 52.1 43.4 33.6
Maximum 97.9 98.6 99.3 99.3
Soreness in your muscles 76.7 78.0 76.5 75.0 2.8 ns
Muscle spasms or twitching 78.9 84.5 77.1 74.3 8.5 0.082
Joint pain 72.8 75.0 80.9 80.0 3.0 ns
Stiffening of joints 77.2 79.7 84.3 84.3 2.6 ns
Ache in boxes 84.2 82.8 84.3 82.9 0.0 ns
Back pain 79.4 81.0 80.0 81.4 0.2 ns
Chest pain 93.5 92.7 95.0 91.4 2.7 ns
Headaches 87.9 85.8 83.6 85.7 4.3 ns
Cramps during an exchange or treatment 86.2 90.1 88.6 83.6 8.9 0.035
Cramps after an exchange or treatment 91.4 92.7 90.7 85.0 7.0 ns
Easy bruising 75.0 79.3 80.9 82.1 3.1 ns
Itchy skin 64.2 67.1 61.8 59.8 4.8 ns
Dry skin 52.7 58.5 59.6 57.6 7.8 ns
Trouble getting your breath 85.3 85.7 85.3 83.3 2.3 ns
Shortness of breath 80.6 80.7 80.9 83.3 2.3 ns
Faintness or dizziness 87.1 91.2 89.0 86.4 6.8 0.082
Lack of appetite 78.9 82.9 80.9 77.3 7.6 ns
Loss of taste 87.5 87.5 90.4 85.6 4.8 ns
Dry mouth 75.9 68.0 75.0 67.4 0.3 ns
Excessive thirst 85.8 80.7 81.6 78.0 1.5 ns
Lack of strength 69.8 68.4 71.3 62.5 7.4 ns
Fatigue, weakness 72.8 70.2 71.3 65.2 3.5 ns
Washed out or drained 75.4 75.0 73.5 67.2 5.9 ns
Numbness in hands or feet 78.4 80.2 79.3 77.2 3.8 ns
Low blood pressure 86.2 85.8 88.6 81.6 6.6 ns
High blood pressure 79.7 83.3 81.7 79.8 5.5 ns
Trouble concentrating or thinking 87.1 88.2 88.6 87.5 2.2 ns
Trouble with memory 85.3 84.9 89.0 86.0 2.6 ns
Swelling of ankles 84.6 87.5 82.9 85.6 0.1 ns
Hot or cold spells 81.6 85.3 84.3 86.8 1.2 ns
Trouble sleeping 70.2 70.2 66.4 66.9 0.5 ns
Sleepiness during the day 71.6 71.9 72.9 73.5 0.3 ns
Blurred vision 87.9 87.9 82.9 82.4 0.5 ns
Nausea or upset stomach 79.4 83.3 77.1 80.9 0.2 ns
Problems with exit site 96.9 92.7 95.7 97.8 6.3 0.006
a Two-sample t test
tients with ESRD. The impact of new therapies on pa- treatment modalities, medical complications, and life
styles afforded by these treatment modalities; (b) case-tient quality of life is emerging as an important indicator
of the value of these therapies. In patients on dialysis, mix differences in patient samples selected; or (c) both.
While PD patients may have a QOL profile superior toprevious QOL evaluations have focused mainly on com-
parative approaches between modalities, or on longitu- HD, they continue to show the burden of the underlying
disease and therapy improvements that can lessen thatdinal trends within a modality but few have evaluated
technical innovations or introduction of new solutions. burden need to be pursued.
This article assessed the early effects of a new dialysisSeveral studies comparing QOL differences between
continuous (PD) and intermittent (HD) dialysis modal- solution on the QOL of peritoneal dialysis patients com-
pared to a control group in a randomized double-blindities have been conducted. The findings of these studies
have recently been evaluated in a meta-analytic ap- trial. Several aspects of our trial make it uniquely suitable
for such an evaluation. The double-blind approach al-proach that made it possible to systematically retrieve
from the literature all published work and establish con- lows for the elimination of bias based on expectation of
benefit, and the use of a control groups tracks secularsensus on QOL differences across RRTs [14]. This ap-
proach had shown that in general PD was characterized trends that may occur spontaneously in this patient popu-
lation.by a greater well being than HD. However, due to lack
of clinical trial data, the study concluded that differential The relevance of our findings to the general PD popu-
lation need to be addressed, particularly the representa-QOL may be attributable to: (a) valid differences in
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Table 6. KDQOL domain/items at baseline, 13 weeks, and changes sure, high blood pressure, dry skin, cramps after an ex-
from baseline to 13 weeks: Clinical meaningful differencesa
change or treatment, cramps during an exchange or treat-
Dextrose Icodextrin ment, and muscle spasms or twitching.
At Baseline: In agreement with the above findings, multivariate
Joint pain Blurred vision analysis showed that icodextrin had contributed statisti-
Stiffening of joints
cally significantly to the improvement of patients’ mentalEasy bruising
Dry skin health, general health, and symptoms such as muscle
At Week 13: spasms or twitching, cramps during an exchange or treat-
Joint pain Muscle spasms or twitching
ment, cramps after an exchange or treatment, itchy skin,Problems with exit site Cramps during an exchange or treatment
Cramps after an exchange or treatment and faintness or dizziness.
Itchy skin Greatest weight should be given to the statistically sig-
Lack of appetite
nificant findings. However, since ESRD patient trials tendLack of strength
Fatigue, weakness to have small sample of patients and QOL as a secondary
Washed out or drained endpoint, it is not uncommon that they are usually under-
Blurred vision
powered for QOL study. Therefore, the MICD findingsBaseline-Week 13
change score: are of particular importance in this patient group. It is
Problems with exit site Muscle spasms or twitching reassuring to note that the MICD findings from this
Cramps during an exchange or treatment
study correspond closely to the results of the multivariateCramps after an exchange or treatment
Dry skin analysis.
Faintness or dizziness It appears that icodextrin patients feel better as a
Lack of appetite
group than those using dextrose, as reflected in theirLack of strength
Washed out or drained health transition score, which measures how they feel
Low blood pressure now rather than a year ago. This is consistent with the
High blood pressure
findings in role-emotional and mental health domains
a Defined as 5-point difference in mean score where icodextrin patients have smaller decline than dex-
trose and have an increase in mental health domain.
Physical functioning and role physical both favor ico-tive nature of the population included in the study. A
dextrin with smaller decline in both domains than dex-comparison of baseline scores for the SF-36 component
trose. In terms of MICD measures, there are also over-for both the dextrose and icodextrin group from our
whelmingly more kidney disease specific items that favorstudy are compared with the corresponding findings of
icodextrin over dextrose. Since there are little differencestwo other studies in the literature and the US population
between patients receiving icodextrin and dextrose in(Table 8) [15]. While all PD populations illustrated in
terms of their demographics, laboratory values and vitalthe Table had measures lower than the normative popu-
sign at baseline, the findings are more likely to havelation scores, the findings within the various PD groups
captured the early QOL benefits of icodextrin.were very comparable, suggesting that no selection bias
It has been shown that ESRD patients’ QOL declinesconfounds our observations.
over time [16]. As time passes, patients are more bur-Overall examination of changes in the SF-36 domains
dened by their kidney disease, feeling more frustratedsuggested that patients receiving icodextrin for the long
by the time spent dealing with their disease, and thedwell had a relatively more favorable change over the
way it interferes with their life. It is important to showperiod of observation than the control group remain-
differences in QOL changes between different therapiesing on dextrose-based solution. This was confirmed by
over time. Therefore longitudinal studies are needed todetailed examination of several other findings in the
obtain insight into the long-term effects of icodextrin onKDQOL instrument. The health transition score showed
PD patients’ quality of life.a decline in health perception among patients on glucose
In the MIDAS study, total symptom scores of icodex-based solution and a better maintenance in the icodextrin
trin group were significantly greater than that in thegroup leading to a statistically significant difference be-
glucose group after four weeks, even though both groupstween the two groups in the mean change from baseline
scored similarly at entry (abstract; Armstrong, ibid). The(P  0.05).
difference continued and increased over the rest of theWhen the kidney disease related symptomatology was
six-month trial. Our findings with KDQOL instrumentexamined, clinically meaningful differences (5 change
reproduce those early findings. Future studies to evaluatein score) tended to favor the icodextrin group in a large
whether the early QOL benefits of icodextrin are sus-number of the symptoms queried, particularly with re-
tained over time need to be pursued.spect to general health perception, physical functioning,
In conclusion, the use of icodextrin in patients on PDrole-physical, lack of strength, washed out or drained,
lack of appetite, faintness or dizziness, low blood pres- is associated with an early QOL of benefit. This QOL
Guo et al: QOL of icodextrin in PD S-79
Table 7. Forward stepwise regression model to explain associations of icodextrin with KDQOL domains/items: coefficient estimates,a partial
explained variance (Partial R2),b and total explained variance (Total R2)c
Cramps during Cramps after
General Mental Muscle spasms an exchange an exchange Itchy Faintness or
health health or twitching or treatment or treatment skin dizziness
Regression coefficient
estimates 9.38 8.13 13.72 8.95 11.08 11.14 7.62
Partial R2 3.16% 4.54% 5.88% 4.18% 4.73% 2.92% 3.30%
Total R2 31.66% 28.94% 33.37% 15.10% 26.83% 29.84% 12.71%
a Only coefficients that were statistically significant at P  0.05 level for icodextrin were reported
b Partial R2 is the percentage of variance in the HRQOL domain/item score that is explained or accounted for by icodextrin only, while controlling for other
demographic and clinical characteristics
c Total R2 is the percentage of the total variation in the HRQOL domain/score that is explained or accounted for by all the demographic, clinical characteristics,
and icodextrin together
Table 8. Comparison of SF-36 domains in various studies in PD
Wight et al. Merkus et al. Dextrose Icodextrin Normative scores
U.S. population
SF-36 domains N  109 N  126 N  35 N  58 N  2472
Physical function 40.6 60.9 57.8 57.2 84.2
Role physical 20.4 31.7 47.8 52.6 80.9
Bodily pain 59.0 74.2 66.3 65.2 75.1
General health 35.1 46.4 46.8 50.5 71.9
Vitality 35.8 51.6 48.3 55.1 60.8
Social function 50.0 68.9 76.1 78.2 83.28
Role emotional 55.5 63.8 61.8 75.3 81.2
Mental health 65.9 72.2 74.6 76.4 74.7
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